Key clinical point: Clear cell papillary renal cell carcinoma (CCPRCC) is a distinct renal tumor type with an apparently indolent clinical course.
Major finding: There were no cases of local recurrence or distant metastasis of CCPRCC after a mean of 49.7 months of follow-up (range 12-119 months).
Study details: Retrospective case study of 25 patients diagnosed and treated at a single center.
Disclosures: The investigators did not report a study funding source. They reported having no conflicts of interest relevant to the subject matter or materials discussed in the article.
Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in Genitourinary Cancer
Obesity-related cancers such as kidney cancer rising among young adults, Sung H et al. Lancet Public Health. 2019 Feb 4.
Treating prostate with radiotherapy boosts survival in advanced prostate cancer, Parker C et al. ESMO 2018, Abstract LBA5_PR
Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10
Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.
Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002